GlassScriptPhysician profile
Donna Ann Robey
NPI 1407841828
$736.65
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $65.41 · 2021: $61.09 · 2022: $176 · 2023: $85.00 · 2024: $21.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $106.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $124.92 | 2022-2023 | Korlym |
| Amgen INC. | $109.93 | 2019-2020 | |
| Abbvie INC. | $81.94 | 2019-2020 | |
| Mission Pharmacal Company | $81.09 | 2019-2020 | |
| Therapeuticsmd, INC. | $46.78 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.21 | 2019-2022 | |
| Daiichi Sankyo INC. | $35.02 | 2019-2022 | |
| Pfizer INC. | $25.39 | 2019 | |
| Nevro Corp. | $25.05 | 2022 | |
| Bardy Diagnostics, INC. | $23.00 | 2022 | |
| Sanofi Pasteur INC. | $21.05 | 2024 | |
| Novo Nordisk INC | $20.68 | 2023 | Wegovy |
| Cranial Technologies, INC | $17.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.31 | 2021 | |
| Avion Pharmaceuticals | $15.58 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $15.20 | 2021 | |
| Corium, LLC | $14.32 | 2023 | Azstarys |
| Duchesnay USA Incorporated | $13.44 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Robey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.